Table 1.

Baseline patient demographics and disease characteristics

	Placebo (N=716) n (%)	Baricitinib 4 mg (N=714) n (%)
Age group (years)
<65	603 (84.2)	578 (81.0)
≥65	113 (15.8)	136 (19.0)
Gender
Female	571 (79.7)	562 (78.7)
Male	145 (20.3)	152 (21.3)
Race
Asian	208 (29.1)	202 (28.3)
White	455 (63.6)	460 (64.4)
Other	52 (7.3)	51 (7.1)
Weight (kg)
<60	219 (30.6)	191 (26.8)
≥60  to <100	436 (60.9)	461 (64.6)
≥ 100	61 (8.5)	62 (8.7)
BMI
≤Median	368 (51.4)	345 (48.3)
>Median	348 (48.6)	368 (51.5)
Tobacco use
Smoker	139 (19.4)	151 (21.2)
Non-smoker	577 (80.6)	562 (78.8)
Time from RA diagnosis (years)
<1	106 (14.8)	114 (16.0)
≥1  and <5	234 (32.7)	233 (32.6)
≥5  and <10	166 (23.2)	166 (23.3)
≥10	210 (29.3)	201 (28.2)
Serology
RF and ACPA (−)	70 (9.8)	71 (9.9)
RF or ACPA (+)	646 (90.2)	643 (90.1)
Previous csDMARD use
≤1	302 (42.2)	342 (47.9)
=2	250 (34.9)	206 (28.9)
≥3	164 (22.9)	166 (23.2)
DAS28-hsCRP score
≤5.1	210 (29.3)	182 (25.5)
>5.1	502 (70.1)	530 (74.2)
SDAI
Lowest tertile	242 (33.8)	223 (31.2)
Middle tertile	240 (33.5)	246 (34.5)
Highest tertile	225 (31.4)	235 (32.9)
HAQ-DI
Lowest tertile	250 (34.9)	256 (35.9)
Middle tertile	262 (36.6)	238 (33.3)
Highest tertile	200 (27.9)	218 (30.5)

ACPA, anticitrullinated peptide antibody; BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-hsCRP, Disease Activity Score for 28 joint counts based on the level of high-sensitivity C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; N, number of modified intent-to-treat patients in the specified treatment population; n, number of patients in specified category; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index.